Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint. However, there are no known published reports about the value of PFS from the patient’s perspective. We deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A., Lalla, Deepa, Crosby, Ross D., Mathias, Susan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855533/
https://www.ncbi.nlm.nih.gov/pubmed/24218050
http://dx.doi.org/10.1007/s10549-013-2734-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855533/
https://www.ncbi.nlm.nih.gov/pubmed/24218050
http://dx.doi.org/10.1007/s10549-013-2734-4

Ejemplares similares